12:11 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Clinical News

Celldex routed after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (2.9 vs. 2.8 months,...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >